FIELD: biotechnology.
SUBSTANCE: what is declared is the use of CD38 specific antibody for treating multiple myeloma, wherein said antibody is introduced in dose of 8 mg/kg to 16 mg/kg once a week (q1w) for at least eight weeks.
EFFECT: invention provides a significant improvement of the overall frequency and length of the response to the treatment in the patients suffering multiple myeloma.
7 cl, 11 dwg, 4 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-CD38 ANTIBODY AND LENALTDOMID OR BORTEZOMIB FOR TREATING MULTIPLE MYELOMA AND NHL | 2011 |
|
RU2595839C2 |
| COMBINATIONS AND THEIR APPLICATION | 2013 |
|
RU2650618C2 |
| ANTIBODIES TO CD38 AND PHARMACEUTICAL COMPOSITIONS BASED THEREON FOR TREATMENT OF AUTOIMMUNE DISEASE MEDIATED BY AUTOANTIBODIES | 2020 |
|
RU2809565C2 |
| COMPOSITIONS COMPRISING ANTIBODY TO CD38 AND CARFILZOMIB | 2014 |
|
RU2670127C2 |
| COMPOSITIONS COMPRISING CD38 ANTIBODIES AND CARFILZOMIB | 2014 |
|
RU2723937C2 |
| COMPOSITIONS CONTAINING ANTIBODIES TO CD38 AND LENALIDOMIDE | 2013 |
|
RU2698911C2 |
| SUBCUTANEOUS DOSING OF ANTI-CD38 ANTIBODIES | 2019 |
|
RU2810953C2 |
| SUBCUTANEOUS INJECTION OF ANTI-CD38 ANTIBODIES | 2019 |
|
RU2782950C2 |
| ANTIBODIES TO CD40 FOR USE IN THE TREATMENT OF SJOGREN'S SYNDROME | 2018 |
|
RU2790558C2 |
| COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
